Bumrungrad Hospital (BH) Q1 2026 (Q&A) earnings summary

Executive summary

• Q1 2026 revenue reached THB 6,254 million, up 1.4% year-over-year, with EBITDA up 5% and EBITDA margin near 40%.

• Net profit attributable to equity holders was THB 1,790 million, up 3.2% year-over-year, with net profit margin at 28.6%.

• Non-Thai patient revenue grew 4.2% year-over-year, with Middle East contributing 22% of total revenue and 66% of revenue from non-Thai patients.

• Bed utilization was around 70%, with 485 available beds and an average length of stay of 4.93 days.

• Recognized as #96 in Newsweek's World's Best Hospitals 2026 and #1 in Thailand for the sixth consecutive year.

Financial highlights

• EBITDA reached THB 2,455 million (+5.0% YoY), with EBITDA margin improving to 39.3% and net profit margin to 28.6%.

• Revenue intensity for Q1 2026 was 7.1%.

• Price increases of 4% were implemented at the start of 2026 to offset wage and cost inflation.

• Accounts receivable days rose to 71.7, mainly due to process changes in Qatar's payment system.

• Cost savings achieved in Q1 were 32% of the annual target.

Outlook and guidance

• Q2 2026 revenue growth guidance is ±2%, with expectations of improved Middle East patient flow post-Ramadan.

• Continued focus on international patient growth, advanced medical technology, and new clinic openings.

• No changes in segment organization or reporting structure for 2026.